Determinación de mieloperoxidasa plasmática en ni？os y adolescentes con Diabetes tipo 1

inflammatory events are implicated in all steps of atherosclerosis evolution, from endothelial dysfunction to plaque formation and its posterior rupture myeloperoxidase (mpo), a main component of the leukocytes azurophilic granules, presents an increased activity when a leucocyte activation occurs, contributing to innate immunity mpo is associated with oxidative stress because it generates reactive oxygen species that alters lipid and proteins, favoring atherogenesis. as diabetic patients present an increased risk of developing cardiovascular disease, the objective of this paper was to evaluate plasma mpo levels in children with type 1 diabetes without clinic evidence of vascular disease. thirty patients (15 m/15 f), mean age and duration of diabetes 11.8 ± 2.1 and 3.9 ± 3.2 years respectively were studied, and compared with a sex-, age- and body mass index-matched controls. in both groups the laboratory parameters evaluated were: wbc count, fasting blood glucose, glycosylated hemoglobin (hba1c), plasma fibrinogen, high sensitivity pcr (upcr) and plasma mpo. increased levels of upcr were found in diabetic patients as compared to the control group (1.9 ± 1.8 mg/l vs. 0,6 ± 0.5 mg/l, p = 0.01). no significant differences were found in leukocytes, fibrinogen and mpo values between both groups [6700 ± 1600/ul vs. 7000 ± 850/ul (p = 0.55); 261 ± 65 mg/dl vs. 252 ± 21 mg/dl (p = 0.65) and 1.23 ± 0.29 uui/ml vs. 1.18 ± 0.19 uui/ml (p = 0.71)] respectively. there was no correlation of mpo with other inflammation markers, or with the time of evolution of the disease. these first results suggest that mpo determination was not sensitive to detect a proinflammatory state, as it is upcr is, in children and adolescents with dt1, without vascular complications. no financial conflicts of interests exist.